SK3 Group, Inc. (PINK SHEETS: SKTO) today announces that its new parent company, Healthcare of Today, Inc., has acquired MacuCLEAR, Inc., a pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye. SK3 has entered into a merger agreement with Healthcare of Today, Inc. under which both companies will merger into a new Nevada corporation, Healthcare of Today, Inc., formed for that purpose.
MC-1101, MacuCLEAR’s primary product compound, is a patented, topically delivered drug for treating and stopping the progression of dry Age-related Macular Degeneration (AMD). MacuCLEAR (www.macuclear.com) has an active IND for MC-1101 and has completed a successful Phase Ib human clinical trial. The company’s groundbreaking work leverages its unique understanding of ocular pharmacology and drug development to advance a pipeline of proprietary pharmaceuticals. MacuCLEAR’s accomplished management team includes CTO George C. Y. Chiou, Ph. D., professor and director of the Institute of Ocular Pharmacology and professor of neuroscience and experimental therapeutics at Texas A&M University System Health Science Center. Dr. Chiou previously led the discovery of Timolol, a pioneering treatment for glaucoma.
Read the full Story at CNN Money